<I>IRF8</I> Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma

Chunli Lu; Gan Liu

doi:doi:10.11648/j.cmr.20221104.14

| Peer-Reviewed

IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma

Chunli Lu, Gan Liu

Published in Clinical Medicine Research (Volume 11, Issue 4)

Received: 18 August 2022 Accepted: 25 August 2022 Published: 27 August 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Interferon regulatory factor 8 (IRF8) is a transcription factor involved in the differentiation of myeloid progenitors. In the current study, we aimed to explore the correlation between IRF8 expression and immune cell infiltration in skin cutaneous melanoma, the single nucleotide variants (SNVs) of this gene, and their association with survival outcomes. Analyses are performed using data from The Cancer Genome Atlas (TCGA)-Skin Cutaneous Melanoma (SKCM), with the platform of Gene Set Cancer Analysis (GSCA). IRF8 expression has an infiltration score of 0.7, suggesting a strong correlation with immune cell infiltration. IRF8 expression had strong positive correlations (Pearson's r ≥ -0.6) with the infiltration of CD4+ T, CD8+ T, Central memory T, Cytotoxic T, T follicular helper, Th1 and induced Tregs cells but presented a strong negative correlation (Pearson's r ≤ -0.6) with the infiltration of Neutrophil cells. 8 out of 468 cases (1.71%) in TCGA-SKCM have deleterious SNVs. The IRF8 mutant group harboring these mutations had significantly shorter progression-free survival (P = 0.03), disease-specific survival (P = 0.0065), and overall survival (P = 0.039) compared to the group with wild-type IRF8. In summary, IRF8 expression might serve as an immune cell infiltration marker in skin cutaneous melanoma. IRF8 deleterious SNVs are associated with significantly worse prognosis. In the future, it is meaningful to validate the link between these mutations and immunotherapy responses.

Published in	Clinical Medicine Research (Volume 11, Issue 4)
DOI	10.11648/j.cmr.20221104.14
Page(s)	109-113
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

IRF8, Skin Cutaneous Melanoma, SNVs, Immune Cell Infiltration, Prognosis

References

[1]	Bertolotto C. Melanoma: from melanocyte to genetic alterations and clinical options [J]. Scientifica (Cairo), 2013, 2013: 635203.
[2]	Joyce D and Skitzki JJ. Surgical Management of Primary Cutaneous Melanoma [J]. Surg Clin North Am, 2020, 100 (1): 61-70.
[3]	Enomoto LM, Levine EA, Shen P, et al. Role of Surgery for Metastatic Melanoma [J]. Surg Clin North Am, 2020, 100 (1): 127-139.
[4]	Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial [J]. Lancet Oncol, 2015, 16 (4): 375-384.
[5]	Luke JJ, Flaherty KT, Ribas A, et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma [J]. Nat Rev Clin Oncol, 2017, 14 (8): 463-482.
[6]	Weiss SA, Wolchok JD and Sznol M. Immunotherapy of Melanoma: Facts and Hopes [J]. Clin Cancer Res, 2019, 25 (17): 5191-5201.
[7]	Edwards J, Wilmott JS, Madore J, et al. CD103 (+) Tumor-Resident CD8 (+) T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment [J]. Clin Cancer Res, 2018, 24 (13): 3036-3045.
[8]	Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study [J]. J Clin Oncol, 2013, 31 (33): 4252-4259.
[9]	Schiavoni G, Gabriele L and Mattei F. The dual role of IRF8 in cancer immunosurveillance [J]. Oncoimmunology, 2013, 2 (8): e25476.
[10]	Mattei F, Schiavoni G, Sestili P, et al. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment [J]. Neoplasia, 2012, 14 (12): 1223-1235.
[11]	Humblin E, Thibaudin M, Chalmin F, et al. IRF8-dependent molecular complexes control the Th9 transcriptional program [J]. Nat Commun, 2017, 8 (1): 2085.
[12]	Twum DY, Colligan SH, Hoffend NC, et al. IFN regulatory factor-8 expression in macrophages governs an antimetastatic program [J]. JCI Insight, 2019, 4 (3).
[13]	Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency [J]. N Engl J Med, 2011, 365 (2): 127-138.
[14]	Cancer Genome Atlas N. Genomic Classification of Cutaneous Melanoma [J]. Cell, 2015, 161 (7): 1681-1696.
[15]	Liu CJ, Hu FF, Xia MX, et al. GSCALite: a web server for gene set cancer analysis [J]. Bioinformatics, 2018, 34 (21): 3771-3772.
[16]	Homet Moreno B, Zaretsky JM, Garcia-Diaz A, et al. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells [J]. Cancer Immunol Res, 2016, 4 (10): 845-857.
[17]	Yamaguchi K, Mishima K, Ohmura H, et al. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody [J]. Cancer Sci, 2018, 109 (10): 3032-3042.
[18]	Shen L, Wu Y, Qi H, et al. Inducible Regulatory T Cell Predicts Efficacy of PD-1 Blockade Therapy in Melanoma [J]. Advanced Therapeutics, 2022, 5 (4): 2100098.
[19]	Chorazy M, Wawrusiewicz-Kurylonek N, Posmyk R, et al. Analysis of chosen SNVs in GPC5, CD58 and IRF8 genes in multiple sclerosis patients [J]. Adv Med Sci, 2019, 64 (2): 230-234.
[20]	De Groen RAL, van Eijk R, Bohringer S, et al. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype [J]. Blood Adv, 2021, 5 (19): 3760-3775.

Cite This Article

Plain Text BibTeX RIS

APA Style

Chunli Lu, Gan Liu. (2022). IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clinical Medicine Research, 11(4), 109-113. https://doi.org/10.11648/j.cmr.20221104.14

Copy | Download

ACS Style

Chunli Lu; Gan Liu. IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clin. Med. Res. 2022, 11(4), 109-113. doi: 10.11648/j.cmr.20221104.14

Copy | Download

AMA Style

Chunli Lu, Gan Liu. IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clin Med Res. 2022;11(4):109-113. doi: 10.11648/j.cmr.20221104.14

Copy | Download

@article{10.11648/j.cmr.20221104.14,
  author = {Chunli Lu and Gan Liu},
  title = {IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma},
  journal = {Clinical Medicine Research},
  volume = {11},
  number = {4},
  pages = {109-113},
  doi = {10.11648/j.cmr.20221104.14},
  url = {https://doi.org/10.11648/j.cmr.20221104.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20221104.14},
  abstract = {Interferon regulatory factor 8 (IRF8) is a transcription factor involved in the differentiation of myeloid progenitors. In the current study, we aimed to explore the correlation between IRF8 expression and immune cell infiltration in skin cutaneous melanoma, the single nucleotide variants (SNVs) of this gene, and their association with survival outcomes. Analyses are performed using data from The Cancer Genome Atlas (TCGA)-Skin Cutaneous Melanoma (SKCM), with the platform of Gene Set Cancer Analysis (GSCA). IRF8 expression has an infiltration score of 0.7, suggesting a strong correlation with immune cell infiltration. IRF8 expression had strong positive correlations (Pearson's r ≥ -0.6) with the infiltration of CD4+ T, CD8+ T, Central memory T, Cytotoxic T, T follicular helper, Th1 and induced Tregs cells but presented a strong negative correlation (Pearson's r ≤ -0.6) with the infiltration of Neutrophil cells. 8 out of 468 cases (1.71%) in TCGA-SKCM have deleterious SNVs. The IRF8 mutant group harboring these mutations had significantly shorter progression-free survival (P = 0.03), disease-specific survival (P = 0.0065), and overall survival (P = 0.039) compared to the group with wild-type IRF8. In summary, IRF8 expression might serve as an immune cell infiltration marker in skin cutaneous melanoma. IRF8 deleterious SNVs are associated with significantly worse prognosis. In the future, it is meaningful to validate the link between these mutations and immunotherapy responses.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma
AU  - Chunli Lu
AU  - Gan Liu
Y1  - 2022/08/27
PY  - 2022
N1  - https://doi.org/10.11648/j.cmr.20221104.14
DO  - 10.11648/j.cmr.20221104.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 109
EP  - 113
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20221104.14
AB  - Interferon regulatory factor 8 (IRF8) is a transcription factor involved in the differentiation of myeloid progenitors. In the current study, we aimed to explore the correlation between IRF8 expression and immune cell infiltration in skin cutaneous melanoma, the single nucleotide variants (SNVs) of this gene, and their association with survival outcomes. Analyses are performed using data from The Cancer Genome Atlas (TCGA)-Skin Cutaneous Melanoma (SKCM), with the platform of Gene Set Cancer Analysis (GSCA). IRF8 expression has an infiltration score of 0.7, suggesting a strong correlation with immune cell infiltration. IRF8 expression had strong positive correlations (Pearson's r ≥ -0.6) with the infiltration of CD4+ T, CD8+ T, Central memory T, Cytotoxic T, T follicular helper, Th1 and induced Tregs cells but presented a strong negative correlation (Pearson's r ≤ -0.6) with the infiltration of Neutrophil cells. 8 out of 468 cases (1.71%) in TCGA-SKCM have deleterious SNVs. The IRF8 mutant group harboring these mutations had significantly shorter progression-free survival (P = 0.03), disease-specific survival (P = 0.0065), and overall survival (P = 0.039) compared to the group with wild-type IRF8. In summary, IRF8 expression might serve as an immune cell infiltration marker in skin cutaneous melanoma. IRF8 deleterious SNVs are associated with significantly worse prognosis. In the future, it is meaningful to validate the link between these mutations and immunotherapy responses.
VL  - 11
IS  - 4
ER  -

Copy | Download

Author Information

Chunli Lu

Department of Cosmetic Dermatology, the Second People’s Hospital of Neijiang, Neijiang, China
Gan Liu

Department of Cosmetic Dermatology, the First People’s Hospital of Neijiang, Neijiang, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Chunli Lu, Gan Liu. (2022). IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clinical Medicine Research, 11(4), 109-113. https://doi.org/10.11648/j.cmr.20221104.14

Copy | Download

ACS Style

Chunli Lu; Gan Liu. IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clin. Med. Res. 2022, 11(4), 109-113. doi: 10.11648/j.cmr.20221104.14

Copy | Download

AMA Style

Chunli Lu, Gan Liu. IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma. Clin Med Res. 2022;11(4):109-113. doi: 10.11648/j.cmr.20221104.14

Copy | Download

@article{10.11648/j.cmr.20221104.14,
  author = {Chunli Lu and Gan Liu},
  title = {IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma},
  journal = {Clinical Medicine Research},
  volume = {11},
  number = {4},
  pages = {109-113},
  doi = {10.11648/j.cmr.20221104.14},
  url = {https://doi.org/10.11648/j.cmr.20221104.14},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cmr.20221104.14},
  abstract = {Interferon regulatory factor 8 (IRF8) is a transcription factor involved in the differentiation of myeloid progenitors. In the current study, we aimed to explore the correlation between IRF8 expression and immune cell infiltration in skin cutaneous melanoma, the single nucleotide variants (SNVs) of this gene, and their association with survival outcomes. Analyses are performed using data from The Cancer Genome Atlas (TCGA)-Skin Cutaneous Melanoma (SKCM), with the platform of Gene Set Cancer Analysis (GSCA). IRF8 expression has an infiltration score of 0.7, suggesting a strong correlation with immune cell infiltration. IRF8 expression had strong positive correlations (Pearson's r ≥ -0.6) with the infiltration of CD4+ T, CD8+ T, Central memory T, Cytotoxic T, T follicular helper, Th1 and induced Tregs cells but presented a strong negative correlation (Pearson's r ≤ -0.6) with the infiltration of Neutrophil cells. 8 out of 468 cases (1.71%) in TCGA-SKCM have deleterious SNVs. The IRF8 mutant group harboring these mutations had significantly shorter progression-free survival (P = 0.03), disease-specific survival (P = 0.0065), and overall survival (P = 0.039) compared to the group with wild-type IRF8. In summary, IRF8 expression might serve as an immune cell infiltration marker in skin cutaneous melanoma. IRF8 deleterious SNVs are associated with significantly worse prognosis. In the future, it is meaningful to validate the link between these mutations and immunotherapy responses.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - IRF8 Deleterious Single Nucleotide Variations Are Associated with Unfavorable Survival of Patients with Skin Cutaneous Melanoma
AU  - Chunli Lu
AU  - Gan Liu
Y1  - 2022/08/27
PY  - 2022
N1  - https://doi.org/10.11648/j.cmr.20221104.14
DO  - 10.11648/j.cmr.20221104.14
T2  - Clinical Medicine Research
JF  - Clinical Medicine Research
JO  - Clinical Medicine Research
SP  - 109
EP  - 113
PB  - Science Publishing Group
SN  - 2326-9057
UR  - https://doi.org/10.11648/j.cmr.20221104.14
AB  - Interferon regulatory factor 8 (IRF8) is a transcription factor involved in the differentiation of myeloid progenitors. In the current study, we aimed to explore the correlation between IRF8 expression and immune cell infiltration in skin cutaneous melanoma, the single nucleotide variants (SNVs) of this gene, and their association with survival outcomes. Analyses are performed using data from The Cancer Genome Atlas (TCGA)-Skin Cutaneous Melanoma (SKCM), with the platform of Gene Set Cancer Analysis (GSCA). IRF8 expression has an infiltration score of 0.7, suggesting a strong correlation with immune cell infiltration. IRF8 expression had strong positive correlations (Pearson's r ≥ -0.6) with the infiltration of CD4+ T, CD8+ T, Central memory T, Cytotoxic T, T follicular helper, Th1 and induced Tregs cells but presented a strong negative correlation (Pearson's r ≤ -0.6) with the infiltration of Neutrophil cells. 8 out of 468 cases (1.71%) in TCGA-SKCM have deleterious SNVs. The IRF8 mutant group harboring these mutations had significantly shorter progression-free survival (P = 0.03), disease-specific survival (P = 0.0065), and overall survival (P = 0.039) compared to the group with wild-type IRF8. In summary, IRF8 expression might serve as an immune cell infiltration marker in skin cutaneous melanoma. IRF8 deleterious SNVs are associated with significantly worse prognosis. In the future, it is meaningful to validate the link between these mutations and immunotherapy responses.
VL  - 11
IS  - 4
ER  -

Copy | Download